{
  "ticker": "KALA",
  "company_name": "KALA BIO, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03596723",
      "title": "KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Ocular Inflammation",
      "start_date": "2018-07-03",
      "completion_date": "2018-10-18",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03616899",
      "title": "Safety and Efficacy of KPI-121 in Subjects With DED",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Kerato Conjunctivitis Sicca",
      "start_date": "2018-07-10",
      "completion_date": "2020-02-05",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02188160",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Dry Eye Syndromes, Keratoconjunctivitis Sicca",
      "start_date": "2014-06",
      "completion_date": "2015-03",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02793817",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Post Surgical Ocular Inflammation and Pain",
      "start_date": "2016-06",
      "completion_date": "2017-03",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02163824",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Ocular Infections, Irritations and Inflammations",
      "start_date": "2014-05",
      "completion_date": "2014-12",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02813265",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Dry Eye Syndromes, Keratoconjunctivitis Sicca",
      "start_date": "2016-06",
      "completion_date": "2017-10",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05136443",
      "title": "Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Corneal Endothelial Dystrophy, Corneal Edema",
      "start_date": "2021-11-23",
      "completion_date": "2023-09-05",
      "enrollment": 0,
      "sponsor": "Price Vision Group"
    },
    {
      "nct_id": "NCT02819284",
      "title": "Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Dry Eye Syndromes, Keratoconjunctivitis Sicca",
      "start_date": "2016-06",
      "completion_date": "2017-09",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02218489",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Blepharitis",
      "start_date": "2014-07",
      "completion_date": "2016-06",
      "enrollment": 0,
      "sponsor": "Kala Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05727878",
      "title": "Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Persistent Corneal Epithelial Defect",
      "start_date": "2023-02-07",
      "completion_date": "2025-10-19",
      "enrollment": 0,
      "sponsor": "Combangio, Inc"
    }
  ],
  "summary": {
    "total_trials": 11,
    "by_phase": {
      "PHASE3": 6,
      "PHASE2": 3,
      "PHASE4": 1,
      "NA": 1
    },
    "by_status": {
      "TERMINATED": 2,
      "COMPLETED": 9
    },
    "active_trials": 0,
    "completed_trials": 9,
    "conditions": [
      "Blepharitis",
      "Corneal Endothelial Dystrophy, Corneal Edema",
      "Dry Eye Syndromes, Keratoconjunctivitis Sicca",
      "Kerato Conjunctivitis Sicca",
      "Ocular Infections, Irritations and Inflammations",
      "Ocular Inflammation",
      "Persistent Corneal Epithelial Defect",
      "Post Surgical Ocular Inflammation and Pain",
      "Retinal Vein Occlusion, Diabetic Macular Edema"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:21.310958",
    "search_query": "KALA BIO, Inc.",
    "url": "https://clinicaltrials.gov/search?term=KALA+BIO,+Inc."
  }
}